Search
Triclocarban
go.drugbank.com/drugs/DB11155ApprovedIt is a bacteriostatic compound that has been found in antibacterial soaps and other personal care products. … In 2017, the US FDA prohibited the marketing of over-the-counter (OTC) consumer antiseptic wash products containing triclocarban due to negative health effects such as bacterial resistance or hormonal
Synonyms: N-(4-chlorophenyl)-N'-(3,4-dichlorophenyl)ureaCYT007-TNFQb
go.drugbank.com/drugs/DB05758ExperimentalCYT007-TNFQb is an active immunization therapy that aims at providing a novel treatment to people suffering from RA or psoriasis. … The vaccine should allow for administration of low amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules.
Pimozide
go.drugbank.com/drugs/DB01100ApprovedA diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic IndexTriheptanoin
go.drugbank.com/drugs/DB11677ApprovedInvestigational[A214812,A214817] Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin. … [L14612] In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly
ISIS 113715
go.drugbank.com/drugs/DB05506InvestigationalISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes. … In early trials, ISIS 113715 induced statistically significant improvements in multiple measures of glucose control along with statistically significant reductions in LDL-cholesterol.
Olaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigational[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell … [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820]
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexTolcapone
go.drugbank.com/drugs/DB00323ApprovedInvestigationalWithdrawnTolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. … It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
International brands: Sen De NingProducts: TASMAR ROCHE TABLETA LACADA DE 100 MG, TASMAR ROCHE TABLETAS LACADAS DE 200 MGInosine pranobex
go.drugbank.com/drugs/DB13156ApprovedInosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.
Categories: Antiinfectives for Systemic UseSertindole
go.drugbank.com/drugs/DB06144ApprovedWithdrawnIt is a phenylindole derivative used in the treatment of schizophrenia. … It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects.
Romidepsin
go.drugbank.com/drugs/DB06176ApprovedInvestigationalRomidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index